APA (7th ed.) Citation

N, S., C, W., L, K., D, M., L, T., M, A., . . . TV, C. (2008). Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 14(2), 240. https://doi.org/10.1002/lt.21362

Chicago Style (17th ed.) Citation

N, Singh, Wannstedt C, Keyes L, Mayher D, Tickerhoof L, Akoad M, Wagener MM, and Cacciarelli TV. "Valganciclovir as Preemptive Therapy for Cytomegalovirus in Cytomegalovirus-seronegative Liver Transplant Recipients of Cytomegalovirus-seropositive Donor Allografts." Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 14, no. 2 (2008): 240. https://doi.org/10.1002/lt.21362.

MLA (9th ed.) Citation

N, Singh, et al. "Valganciclovir as Preemptive Therapy for Cytomegalovirus in Cytomegalovirus-seronegative Liver Transplant Recipients of Cytomegalovirus-seropositive Donor Allografts." Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, vol. 14, no. 2, 2008, p. 240, https://doi.org/10.1002/lt.21362.